Jane A. Gross's Insider Trades & SAST Disclosures
Jane A. Gross's most recent trade in Atyr Pharma Inc was a trade of 50,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on May 1, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Jane A. Gross.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Atyr Pharma Inc | Jane A. Gross | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2025 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Atyr Pharma Inc | Jane A. Gross | Director | Purchase of securities on an exchange or from another person at price $ 4.00 per share. | 17 Mar 2025 | 3,750 | 9,750 (0%) | 0% | 4 | 15,000 | Common Stock |
| Atyr Pharma Inc | Jane A. Gross | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2024 | 24,000 | 24,000 | - | - | Stock Option (right to buy) | |
| Atyr Pharma Inc | Jane A. Gross | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2023 | 12,000 | 12,000 | - | - | Stock Option (right to buy) | |
| Atyr Pharma Inc | Jane A. Gross | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Apr 2023 | 6,000 | 6,000 (0%) | 0% | - | Common stock | |
| Atyr Pharma Inc | Jane A. Gross | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Apr 2023 | 6,000 | 0 | - | - | Restricted Stock Unit | |
| Atyr Pharma Inc | Jane A. Gross | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Apr 2022 | 6,000 | 6,000 | - | - | Restricted Stock Units | |
| Atyr Pharma Inc | Jane A. Gross | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Apr 2021 | 1,428 | 1,428 | - | - | Stock Option (right to buy) | |
| Aptevo Therapeutics Inc | Jane A. Gross | SVP & Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jan 2021 | 16,500 | 16,500 | - | - | Stock Option (right to buy) | |
| Aptevo Therapeutics Inc | Jane A. Gross | SVP & Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jan 2021 | 5,500 | 5,500 | - | - | Restricted Stock Unit | |
| Aptevo Therapeutics Inc | Jane A. Gross | SVP & Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jul 2020 | 7,784 | 7,784 | - | - | Stock Option (right to buy) | |
| Aptevo Therapeutics Inc | Jane A. Gross | SVP & Chief Scientific Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jul 2020 | 4,814 | 0 | - | - | Stock Option (right to buy) | |
| Aptevo Therapeutics Inc | Jane A. Gross | SVP & Chief Scientific Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jul 2020 | 4,814 | 0 | - | - | Stock Option (right to buy) | |
| Aptevo Therapeutics Inc | Jane A. Gross | SVP & Chief Scientific Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jul 2020 | 3,908 | 0 | - | - | Stock Option (right to buy) | |
| Aptevo Therapeutics Inc | Jane A. Gross | SVP & Chief Scientific Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jul 2020 | 2,779 | 0 | - | - | Stock Option (right to buy) | |
| Aptevo Therapeutics Inc | Jane A. Gross | SVP & Chief Scientific Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jul 2020 | 2,407 | 0 | - | - | Stock Option (right to buy) | |
| Aptevo Therapeutics Inc | Jane A. Gross | SVP & Chief Scientific Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jul 2020 | 2,407 | 0 | - | - | Stock Option (right to buy) | |
| Aptevo Therapeutics Inc | Jane A. Gross | SVP & Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jul 2020 | 2,140 | 2,140 | - | - | Stock Option (right to buy) | |
| Aptevo Therapeutics Inc | Jane A. Gross | SVP & Chief Scientific Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jul 2020 | 2,072 | 0 | - | - | Stock Option (right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges